Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.

Cancer gene therapy - 1 Jul 2017

Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, Shirakawa T

Abstract excerpt

Recently, the US FDA approved sipuleucel-T, which is composed of autologous DCs stimulated with a recombinant fusion protein of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), as the first immunotherapeutic agent for metastatic castration resistant prostate cancer (mCRPC). However, sipuleucel-T demonstrated only modest efficacy in mCPRC patients. Researchers are now...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Dendritic Cells

Share to Genetic Therapy

Share to Perforin

Share to Prostatic Neoplasms

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 28621316
DOI: 10.1038/cgt.2017.21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro.PMID 28621316Read ↗

DNA vaccines for the treatment of prostate cancerSemantic proximity Read ↗

Boosting the Immune Response – Combining the Local and Immune Therapy for Prostate Cancer TreatmentSemantic proximity Read ↗

Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer GrowthSemantic proximity Read ↗

Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate CancerSemantic proximity Read ↗

Induced pluripotent stem cell-derived dendritic cell vaccine therapy genetically modified on the ubiquitin-proteasome systemSemantic proximity Read ↗

Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.Semantic proximity Read ↗

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigenSemantic proximity Read ↗

Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen‐specific CD8<sup>+</sup> T‐cell response and inhibits the PSCA<sup>+</sup> tumors growth in miceSemantic proximity Read ↗

Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.Semantic proximity Read ↗

Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.Semantic proximity Read ↗

Molecular Characterization of Defective Antigen Processing in Human Prostate CancerSemantic proximity Read ↗

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.